Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Individualized Treatment for Relapsed/Refractory Acute Leukemia Based on Chemosensitivity and Genomics/Gene Expression Data

NCT02551718 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT02551718
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02551718 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Individualized Treatment for Relapsed/Refractory Acute Leukemia Based on Chemosensitivity and Genomics/Gene Expression Data
Lead sponsor
University of Washington
Phase
Not applicable
Overall status
Completed
Start date
September 11, 2015
Completion date
May 13, 2021
Enrollment
34 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent acute leukemia of ambiguous lineage, recurrent acute lymphoblastic leukemia, recurrent acute myeloid leukemia, refractory acute leukemia of ambiguous lineage, refractory acute lymphoblastic leukemia, refractory acute myeloid leukemia